TWD 16.15
(0.31%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -47.11 Million TWD | 35.54% |
2022 | -115.03 Million TWD | -47.44% |
2021 | -78.02 Million TWD | 34.25% |
2020 | -118.65 Million TWD | 30.58% |
2019 | -170.92 Million TWD | 6.33% |
2018 | -182.47 Million TWD | 11.57% |
2017 | -206.34 Million TWD | -6.08% |
2016 | -194.51 Million TWD | 4.41% |
2015 | -203.5 Million TWD | 36.74% |
2014 | -321.7 Million TWD | -75.83% |
2013 | -182.96 Million TWD | -76.28% |
2012 | -103.79 Million TWD | 38.97% |
2011 | -170.07 Million TWD | 20.94% |
2010 | -215.11 Million TWD | 19.45% |
2009 | -267.05 Million TWD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | -27.96 Million TWD | 20.56% |
2024 Q2 | -15.86 Million TWD | 43.28% |
2024 Q3 | -24.31 Million TWD | 30.16% |
2023 Q3 | 7.29 Million TWD | 148.4% |
2023 Q4 | -35.2 Million TWD | -582.85% |
2023 FY | -74.14 Million TWD | 35.54% |
2023 Q1 | -7.42 Million TWD | 85.06% |
2023 Q2 | -15.06 Million TWD | -102.77% |
2022 Q2 | -25.92 Million TWD | 24.29% |
2022 Q3 | -5.15 Million TWD | 80.14% |
2022 Q4 | -49.71 Million TWD | -865.34% |
2022 Q1 | -34.24 Million TWD | -4.41% |
2022 FY | -115.03 Million TWD | -47.44% |
2021 Q2 | -26.61 Million TWD | -3.79% |
2021 Q4 | -32.79 Million TWD | -547.02% |
2021 FY | -78.02 Million TWD | 34.25% |
2021 Q1 | -25.64 Million TWD | 5.02% |
2021 Q3 | 7.33 Million TWD | 127.57% |
2020 Q3 | -28.84 Million TWD | -1081.39% |
2020 Q2 | 2.93 Million TWD | 108.32% |
2020 Q1 | -35.34 Million TWD | 53.18% |
2020 Q4 | -26.99 Million TWD | 6.41% |
2020 FY | -118.65 Million TWD | 30.58% |
2019 Q3 | -39.74 Million TWD | -65.53% |
2019 FY | -170.92 Million TWD | 6.33% |
2019 Q1 | -31.5 Million TWD | 61.67% |
2019 Q2 | -24 Million TWD | 23.8% |
2019 Q4 | -75.49 Million TWD | -89.97% |
2018 Q2 | -26.82 Million TWD | 22.58% |
2018 FY | -182.47 Million TWD | 11.57% |
2018 Q4 | -82.21 Million TWD | -111.94% |
2018 Q3 | -38.79 Million TWD | -44.6% |
2018 Q1 | -34.65 Million TWD | 62.75% |
2017 Q3 | -36.97 Million TWD | -3.38% |
2017 FY | -206.34 Million TWD | -6.08% |
2017 Q2 | -35.77 Million TWD | 11.84% |
2017 Q4 | -93.02 Million TWD | -151.55% |
2017 Q1 | -40.57 Million TWD | 28.49% |
2016 Q1 | -55.34 Million TWD | -43.74% |
2016 FY | -194.51 Million TWD | 4.41% |
2016 Q3 | -30.15 Million TWD | 42.3% |
2016 Q4 | -56.74 Million TWD | -88.14% |
2016 Q2 | -52.27 Million TWD | 5.56% |
2015 Q1 | -69.83 Million TWD | 27.34% |
2015 Q2 | -58.92 Million TWD | 15.63% |
2015 Q3 | -36.23 Million TWD | 38.5% |
2015 Q4 | -38.5 Million TWD | -6.26% |
2015 FY | -203.5 Million TWD | 36.74% |
2014 Q4 | -96.12 Million TWD | -23.66% |
2014 Q2 | -113.02 Million TWD | -224.51% |
2014 FY | -321.7 Million TWD | -75.83% |
2014 Q1 | -34.82 Million TWD | 70.79% |
2014 Q3 | -77.73 Million TWD | 31.22% |
2013 Q3 | -43.48 Million TWD | -50.05% |
2013 Q1 | 8.74 Million TWD | 119.93% |
2013 FY | -182.96 Million TWD | -76.28% |
2013 Q4 | -119.24 Million TWD | -174.22% |
2013 Q2 | -28.98 Million TWD | -431.39% |
2012 Q3 | -8.08 Million TWD | 70.12% |
2012 Q2 | -27.07 Million TWD | -9.35% |
2012 Q1 | -24.76 Million TWD | 58.79% |
2012 Q4 | -43.86 Million TWD | -442.33% |
2012 FY | -103.79 Million TWD | 38.97% |
2011 Q1 | -31.56 Million TWD | 68.1% |
2011 FY | -170.07 Million TWD | 20.94% |
2011 Q4 | -60.08 Million TWD | -24.77% |
2011 Q3 | -48.15 Million TWD | -59.12% |
2011 Q2 | -30.26 Million TWD | 4.12% |
2010 FY | -215.11 Million TWD | 19.45% |
2010 Q4 | -98.94 Million TWD | -103.13% |
2010 Q1 | -36.05 Million TWD | 0.0% |
2010 Q2 | -31.4 Million TWD | 12.9% |
2010 Q3 | -48.7 Million TWD | -55.08% |
2009 FY | -267.05 Million TWD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Grape King Bio Ltd | 1.45 Billion TWD | 103.243% |
Standard Chem & Pharm CO., LTD. | 834.88 Million TWD | 105.644% |
Maywufa Company Ltd. | 169.09 Million TWD | 127.864% |
ScinoPharm Taiwan, Ltd. | 287.05 Million TWD | 116.414% |
Lotus Pharmaceutical Co., Ltd. | 4.1 Billion TWD | 101.148% |
LIWANLI Innovation Co., Ltd. | 5.1 Million TWD | 1023.32% |
YungShin Global Holding Corporation | 827.3 Million TWD | 105.695% |
SCI Pharmtech, Inc. | 294.72 Million TWD | 115.987% |
Formosa Laboratories, Inc. | 126.24 Million TWD | 137.322% |
PharmaEssentia Corporation | -623.83 Million TWD | 92.447% |
Bora Pharmaceuticals Co., LTD. | 3.03 Billion TWD | 101.555% |